A tetravalent live attenuated dengue virus vaccine stimulates balanced immunity to multiple serotypes in humans
Usha K Nivarthi, Jesica Swanstrom, Matthew J Delacruz, Bhumi Patel, Anna P Durbin, Steve S Whitehead, Beth D Kirkpatrick, Kristen K Pierce, Sean A Diehl, Leah Katzelnick, Ralph S Baric, Aravinda M de Silva, Usha K Nivarthi, Jesica Swanstrom, Matthew J Delacruz, Bhumi Patel, Anna P Durbin, Steve S Whitehead, Beth D Kirkpatrick, Kristen K Pierce, Sean A Diehl, Leah Katzelnick, Ralph S Baric, Aravinda M de Silva
Abstract
The four-dengue virus (DENV) serotypes infect several hundred million people annually. For the greatest safety and efficacy, tetravalent DENV vaccines are designed to stimulate balanced protective immunity to all four serotypes. However, this has been difficult to achieve. Clinical trials with a leading vaccine demonstrated that unbalanced replication and immunodominance of one vaccine component over others can lead to low efficacy and vaccine enhanced severe disease. The Laboratory of Infectious Diseases at the National Institutes of Health has developed a live attenuated tetravalent DENV vaccine (TV003), which is currently being tested in phase 3 clinical trials. Here we report, our study to determine if TV003 stimulate balanced and serotype-specific (TS) neutralizing antibody (nAb) responses to each serotype. Serum samples from twenty-one dengue-naive individuals participated under study protocol CIR287 (ClinicalTrials.gov NCT02021968) are analyzed 6 months after vaccination. Most subjects (76%) develop TS nAbs to 3 or 4 DENV serotypes, indicating immunity is induced by each vaccine component. Vaccine-induced TS nAbs map to epitopes known to be targets of nAbs in people infected with wild type DENVs. Following challenge with a partially attenuated strain of DENV2, all 21 subjects are protected from the efficacy endpoints. However, some vaccinated individuals develop post challenge nAb boost, while others mount post-challenge antibody responses that are consistent with sterilizing immunity. TV003 vaccine induced DENV2 TS nAbs are associated with sterilizing immunity. Our results indicate that nAbs to TS epitopes on each serotype may be a better correlate than total levels of nAbs currently used for guiding DENV vaccine development.
Conflict of interest statement
A.M.D. has consulted on Dengue vaccine for Takeda vaccines, Sanofi Pasteur, GSK, and Merck Pharmaceuticals and also an inventor in patents related to Dengue vaccines. R.S.B. has consulted on Dengue vaccines for Takeda Vaccines and Sanofi Pasteur and is also an inventor in patents related to Dengue vaccines. All other authors report no potential conflicts of interest.
Figures
References
- Bhatt S, et al. The global distribution and burden of dengue. Nature. 2013;496:504–507. doi: 10.1038/nature12060.
- Radke EG, et al. Dengue outbreak in Key West, Florida, USA, 2009. Emerg. Infect. Dis. 2012;18:135–137. doi: 10.3201/eid1801.110130.
- Schaffner F, Mathis A. Dengue and dengue vectors in the WHO European region: past, present, and scenarios for the future. Lancet Infect. Dis. 2014;14:1271–1280. doi: 10.1016/S1473-3099(14)70834-5.
- Sabin AB. Research on dengue during World War II. Am. J. Trop. Med. Hyg. 1952;1:30–50. doi: 10.4269/ajtmh.1952.1.30.
- Montoya M, et al. Symptomatic versus inapparent outcome in repeat dengue virus infections is influenced by the time interval between infections and study year. PLoS Negl. Trop. Dis. 2013;7:e2357. doi: 10.1371/journal.pntd.0002357.
- Halstead SB. Etiologies of the experimental dengues of Siler and Simmons. Am. J. Trop. Med. Hyg. 1974;23:974–982. doi: 10.4269/ajtmh.1974.23.974.
- Guzman MG, et al. Epidemiologic studies on Dengue in Santiago de Cuba, 1997. Am. J. Epidemiol. 2000;152:793–799. doi: 10.1093/aje/152.9.793.
- de Alwis R, et al. In-depth analysis of the antibody response of individuals exposed to primary dengue virus infection. PLoS Negl. Trop. Dis. 2011;5:e1188. doi: 10.1371/journal.pntd.0001188.
- de Alwis R, et al. Dengue viruses are enhanced by distinct populations of serotype cross-reactive antibodies in human immune sera. PLoS Pathog. 2014;10:e1004386. doi: 10.1371/journal.ppat.1004386.
- Larsen CP, Whitehead SS, Durbin AP. Dengue human infection models to advance dengue vaccine development. Vaccine. 2015;33:7075–7082. doi: 10.1016/j.vaccine.2015.09.052.
- Kirkpatrick BD, et al. The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model. Sci. Transl. Med. 2016;8:330ra336. doi: 10.1126/scitranslmed.aaf1517.
- Capeding MR, et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet. 2014;384:1358–1365. doi: 10.1016/S0140-6736(14)61060-6.
- Hadinegoro SR, et al. Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N. Engl. J. Med. 2015;373:1195–1206. doi: 10.1056/NEJMoa1506223.
- Sridhar S, et al. Effect of dengue serostatus on dengue vaccine safety and efficacy. N. Engl. J. Med. 2018;379:327–340. doi: 10.1056/NEJMoa1800820.
- Guirakhoo F, et al. Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates. Virology. 2002;298:146–159. doi: 10.1006/viro.2002.1462.
- Guy B, et al. Evaluation of interferences between dengue vaccine serotypes in a monkey model. Am. J. Trop. Med. Hyg. 2009;80:302–311. doi: 10.4269/ajtmh.2009.80.302.
- Osorio JE, et al. Efficacy of a tetravalent chimeric dengue vaccine (DENVax) in Cynomolgus macaques. Am. J. Trop. Med. Hyg. 2011;84:978–987. doi: 10.4269/ajtmh.2011.10-0592.
- Morrison D, et al. A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults. J. Infect. Dis. 2010;201:370–377. doi: 10.1086/649916.
- Dayan GH, et al. Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naive adults in Mexico. Hum. Vaccin. Immunother. 2014;10:2853–2863. doi: 10.4161/21645515.2014.972131.
- Torresi J, et al. Replication and excretion of the live attenuated tetravalent dengue vaccine CYD-TDV in a flavivirus-naive adult population: assessment of vaccine viremia and virus shedding. J. Infect. Dis. 2017;216:834–841. doi: 10.1093/infdis/jix314.
- Henein S, et al. Dissecting antibodies induced by a chimeric yellow fever-dengue, live-attenuated, tetravalent dengue vaccine (CYD-TDV) in naive and dengue-exposed individuals. J. Infect. Dis. 2017;215:351–358.
- Dayan GH, et al. Assessment of the long-term efficacy of a dengue vaccine against symptomatic, virologically-confirmed dengue disease by baseline dengue serostatus. Vaccine. 2020;38:3531–3536. doi: 10.1016/j.vaccine.2020.03.029.
- Durbin AP, et al. A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trial. J. Infect. Dis. 2013;207:957–965. doi: 10.1093/infdis/jis936.
- Durbin AP, et al. rDEN4delta30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers. J. Infect. Dis. 2005;191:710–718. doi: 10.1086/427780.
- Durbin AP, et al. rDEN2/4Delta30(ME), a live attenuated chimeric dengue serotype 2 vaccine is safe and highly immunogenic in healthy dengue-naive adults. Hum. Vaccin. 2006;2:255–260. doi: 10.4161/hv.2.6.3494.
- Durbin AP, et al. The live attenuated dengue serotype 1 vaccine rDEN1Delta30 is safe and highly immunogenic in healthy adult volunteers. Hum. Vaccin. 2006;2:167–173. doi: 10.4161/hv.2.4.2944.
- Durbin AP, Kirkpatrick BD, Pierce KK, Schmidt AC, Whitehead SS. Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine. Vaccine. 2011;29:7242–7250. doi: 10.1016/j.vaccine.2011.07.023.
- Kirkpatrick BD, et al. Robust and balanced immune responses to all 4 dengue virus serotypes following administration of a single dose of a live attenuated tetravalent dengue vaccine to healthy, flavivirus-naive adults. J. Infect. Dis. 2015;212:702–710. doi: 10.1093/infdis/jiv082.
- Gallichotte EN, et al. Genetic variation between dengue virus type 4 strains impacts human antibody binding and neutralization. Cell Rep. 2018;25:1214–1224. doi: 10.1016/j.celrep.2018.10.006.
- Fibriansah G, et al. A potent anti-dengue human antibody preferentially recognizes the conformation of E protein monomers assembled on the virus surface. EMBO Mol. Med. 2014;6:358–371. doi: 10.1002/emmm.201303404.
- Fibriansah G, et al. DENGUE VIRUS. Cryo-EM structure of an antibody that neutralizes dengue virus type 2 by locking E protein dimers. Science. 2015;349:88–91. doi: 10.1126/science.aaa8651.
- Fibriansah G, et al. A highly potent human antibody neutralizes dengue virus serotype 3 by binding across three surface proteins. Nat. Commun. 2015;6:6341. doi: 10.1038/ncomms7341.
- Nivarthi, U. K. et al. Mapping the human memory B cell and serum neutralizing antibody responses to dengue virus serotype 4 infection and vaccination. J. Virol. 9110.1128/JVI.02041-16 (2017).
- Swanstrom JA, et al. Beyond neutralizing antibody levels: the epitope specificity of antibodies induced by national institutes of health monovalent dengue virus vaccines. J. Infect. Dis. 2019;220:219–227. doi: 10.1093/infdis/jiz109.
- Gallichotte EN, et al. A new quaternary structure epitope on dengue virus serotype 2 is the target of durable type-specific neutralizing antibodies. MBio. 2015;6:e01461-01415. doi: 10.1128/mBio.01461-15.
- Gallichotte EN, et al. Human dengue virus serotype 2 neutralizing antibodies target two distinct quaternary epitopes. PLoS Pathog. 2018;14:e1006934. doi: 10.1371/journal.ppat.1006934.
- Widman DG, et al. Transplantation of a quaternary structure neutralizing antibody epitope from dengue virus serotype 3 into serotype 4. Sci. Rep. 2017;7:17169. doi: 10.1038/s41598-017-17355-5.
- Lai CJ, et al. Epitope determinants of a chimpanzee dengue virus type 4 (DENV-4)-neutralizing antibody and protection against DENV-4 challenge in mice and rhesus monkeys by passively transferred humanized antibody. J. Virol. 2007;81:12766–12774. doi: 10.1128/JVI.01420-07.
- Dejnirattisai W, et al. A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus. Nat. Immunol. 2015;16:170–177. doi: 10.1038/ni.3058.
- Smith SA, et al. Isolation of dengue virus-specific memory B cells with live virus antigen from human subjects following natural infection reveals the presence of diverse novel functional groups of antibody clones. J. Virol. 2014;88:12233–12241. doi: 10.1128/JVI.00247-14.
- Guy B, Briand O, Lang J, Saville M, Jackson N. Development of the Sanofi Pasteur tetravalent dengue vaccine: one more step forward. Vaccine. 2015;33:7100–7111. doi: 10.1016/j.vaccine.2015.09.108.
- Osorio JE, et al. Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study. Lancet Infect. Dis. 2014;14:830–838. doi: 10.1016/S1473-3099(14)70811-4.
- Osorio JE, Wallace D, Stinchcomb DT. A recombinant, chimeric tetravalent dengue vaccine candidate based on a dengue virus serotype 2 backbone. Expert Rev. Vaccines. 2016;15:497–508. doi: 10.1586/14760584.2016.1128328.
- Moodie Z, et al. Neutralizing antibody correlates analysis of tetravalent dengue vaccine efficacy trials in Asia and Latin America. J. Infect. Dis. 2018;217:742–753. doi: 10.1093/infdis/jix609.
- Biswal S, et al. Efficacy of a tetravalent dengue vaccine in healthy children and adolescents. N. Engl. J. Med. 2019;381:2009–2019. doi: 10.1056/NEJMoa1903869.
- Swanstrom JA, et al. Beyond neutralizing antibody levels: the epitope specificity of antibodies induced by NIH monovalent dengue virus vaccines. J. Infect. Dis. 2019 doi: 10.1093/infdis/jiz109.
- Lindow JC, et al. Vaccination of volunteers with low-dose, live-attenuated, dengue viruses leads to serotype-specific immunologic and virologic profiles. Vaccine. 2013;31:3347–3352. doi: 10.1016/j.vaccine.2013.05.075.
- Wahala WM, Kraus AA, Haymore LB, Accavitti-Loper MA, de Silva AM. Dengue virus neutralization by human immune sera: role of envelope protein domain III-reactive antibody. Virology. 2009;392:103–113. doi: 10.1016/j.virol.2009.06.037.
- de Alwis R, et al. Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions. Proc. Natl Acad. Sci. USA. 2012;109:7439–7444. doi: 10.1073/pnas.1200566109.
- Swanstrom, J. A. et al. Dengue virus envelope dimer epitope monoclonal antibodies isolated from dengue patients are protective against Zika virus. MBio7, 10.1128/mBio.01123-16 (2016).
- Collins MH, et al. Lack of durable cross-neutralizing antibodies against Zika virus from dengue virus infection. Emerg. Infect. Dis. 2017;23:773–781. doi: 10.3201/eid2305.161630.
- Messer WB, et al. Functional transplant of a dengue virus serotype 3 (DENV3)-specific human monoclonal antibody epitope into DENV1. J. Virol. 2016;90:5090–5097. doi: 10.1128/JVI.00155-16.
- Messer WB, et al. Development and characterization of a reverse genetic system for studying dengue virus serotype 3 strain variation and neutralization. PLoS Negl. Trop. Dis. 2012;6:e1486. doi: 10.1371/journal.pntd.0001486.
Source: PubMed